Captopril
Capoten, Capozide (captopril) is a small molecule pharmaceutical. Captopril was first approved as Capoten on 1982-01-01. It is used to treat bartter syndrome, diabetic nephropathies, edema, heart failure, and left ventricular dysfunction amongst others in the USA. The pharmaceutical is active against angiotensin-converting enzyme.
Download report
Favorite
Searched
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Captopril
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CAPOTEN | Strides Pharma Global | N-018343 DISCN | 1982-01-01 | 7 products, RLD |
Hide discontinued
Captopril
+
Hydrochlorothiazide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CAPOZIDE 25/15 | Bristol Myers Squibb | N-018709 DISCN | 1984-10-12 | 1 products, RLD |
| CAPOZIDE 25/25 | Bristol Myers Squibb | N-018709 DISCN | 1984-10-12 | 1 products, RLD |
| CAPOZIDE 50/25 | Bristol Myers Squibb | N-018709 DISCN | 1984-10-12 | 1 products, RLD |
| CAPOZIDE 50/15 | Bristol Myers Squibb | N-018709 DISCN | 1984-10-12 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| captopril | ANDA | 2023-04-20 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| bartter syndrome | Orphanet_112 | D001477 | E26.81 |
| diabetic nephropathies | EFO_0000401 | D003928 | — |
| edema | — | D004487 | R60.9 |
| heart failure | EFO_0003144 | D006333 | I50 |
| left ventricular dysfunction | — | D018487 | — |
| malignant hypertension | EFO_1001031 | D006974 | — |
| raynaud disease | EFO_1001145 | D011928 | I73.0 |
| rheumatoid arthritis | EFO_0000685 | D001172 | M06.9 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
40 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 3 | — | — | 1 | 1 | 5 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | 1 | — | 2 | — | 3 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | 1 | 1 | 1 | 3 |
| Hyperaldosteronism | D006929 | HP_0011736 | E26 | — | — | — | 1 | 2 | 3 |
| Retinal diseases | D012164 | HP_0000479 | H35.9 | — | — | — | 1 | — | 1 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | 1 | — | 1 |
| Inflammation | D007249 | — | — | — | 1 | — | 1 | ||
| Left ventricular dysfunction | D018487 | — | — | — | 1 | — | 1 | ||
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | 1 | — | 1 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | — | — | 1 | — | 1 |
Show 4 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 1 | 1 | 1 | — | — | 2 | |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | 1 | 1 | — | — | 1 | |
| Myeloid leukemia acute | D015470 | C92.0 | — | — | 1 | — | — | 1 | |
| Cardiotoxicity | D066126 | EFO_1001482 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | U07.1 | — | 2 | — | — | — | 2 | |
| Glioblastoma | D005909 | EFO_0000515 | 1 | 1 | — | — | — | 1 | |
| Essential hypertension | D000075222 | I10 | 1 | 1 | — | — | — | 1 | |
| Primary myelofibrosis | D055728 | D47.4 | 1 | 1 | — | — | — | 1 | |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | 1 | — | — | — | 1 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | 1 | — | — | — | 1 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | — | — | — | 1 |
| Lung neoplasms | D008175 | C34.90 | — | 1 | — | — | — | 1 | |
| Radiation pneumonitis | D017564 | EFO_1001411 | J70.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 3 | — | — | — | — | 3 | ||
| Blood pressure | D001794 | EFO_0004325 | 1 | — | — | — | — | 1 | |
| Pure autonomic failure | D054970 | 1 | — | — | — | — | 1 | ||
| Multiple system atrophy | D019578 | 1 | — | — | — | — | 1 | ||
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 1 | 1 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | — | 1 | 1 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | — | 1 | 1 |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CAPTOPRIL |
| INN | captopril |
| Description | Captopril is a L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug. It has a role as an EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor and an antihypertensive agent. It is a pyrrolidinemonocarboxylic acid, a N-acylpyrrolidine, an alkanethiol and a L-proline derivative. |
| Classification | Small molecule |
| Drug class | aptamers, classical and mirror; antihypertensives (ACE inhibitors) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O |
Identifiers
| PDB | 1J37 |
| CAS-ID | 62571-86-2 |
| RxCUI | 1998 |
| ChEMBL ID | CHEMBL1560 |
| ChEBI ID | 3380 |
| PubChem CID | 44093 |
| DrugBank | DB01197 |
| UNII ID | 9G64RSX1XD (ChemIDplus, GSRS) |
Target
Agency Approved
ACE
ACE
Organism
Homo sapiens
Gene name
ACE
Gene synonyms
DCP, DCP1
NCBI Gene ID
Protein name
angiotensin-converting enzyme
Protein synonyms
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1, carboxycathepsin, CD143, CD143 antigen, dipeptidyl carboxypeptidase 1, Dipeptidyl carboxypeptidase I, Kininase II, peptidase P
Uniprot ID
Mouse ortholog
Ace (11421)
angiotensin-converting enzyme (P09470)
Alternate
No data
Variants
Clinical Variant
Identifier | Target mutation | Effect | Evaluation | Status |
|---|---|---|---|---|
| VCV000375659 | ACE, 2306-105_2306-104insTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCCATACAGTCACTTTT | drug response | 2021-03-24 | 2A |
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 18,563 documents
View more details
Safety
Black-box Warning
Black-box warning for: Captopril
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more